Eton Pharmaceuticals (ETON) said Tuesday it has out-licensed commercial rights to Increlex in territories outside of the US to Esteve Pharmaceuticals.
Increlex is indicated for the treatment of growth failure in certain pediatric patients.
Financial terms were not disclosed.
Under the terms of the deal, Esteve will license non-US Increlex rights for up to 10 years and will receive an option to acquire the international rights in the future, the company said, adding it will supply the product to Esteve at a fixed transfer price.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。